In recent years, peptide aptamers have emerged as novel molecular tools that are useful for both basic and applied aspects of molecular medicine. Due to their ability to specifically bind to and inactivate a given target protein at the intracellular level, they provide a new experimental strategy for functional protein analyses, both in vitro and in vivo. In addition, by using peptide aptamers as "pertubagens", they can be employed for genetic analyses, in order to identify biochemical pathways, and their components, that are associated with the induction of distinct cellular phenotypes. Furthermore, peptide aptamers may be developed into diagnostic tools for the detection of a given target protein or for the generation of high-throughput protein arrays. Finally, the peptide aptamer technology has direct therapeutic implications. Peptide aptamers can be used in order to validate therapeutic targets at the intracellular level. Moreover, the peptide aptamer molecules themselves should possess therapeutic potential, both as lead structures for drug design and as a basis for the development of protein drugs.
INTRODUCTION
Peptide aptamers (from Latin aptus, "fitting") are proteinaceous agents that are selected for specific binding to a given target protein, under intracellular conditions. Typically, peptide aptamers consist of a short variable peptide domain presented in the context of a supporting protein scaffold [1, 2] . Thus, in principle, peptide aptamers resemble antibodies, in which a variable antigen-binding domain is exposed from a rigid protein backbone. Peptide aptamers have been shown to bind to their target proteins with significant affinity and high specificity, both in vitro and in vivo. Most importantly, they have also been shown to possess the capability to specifically block the function of their target proteins in vitro, as well as in living cells, and even in whole animals. Notably, neither the structure of the target protein nor its natural interaction partners have to be known in order to generate inhibitory peptide aptamers. Importantly, in the screening procedure, peptide aptamers are isolated together with their coding sequences, thereby resulting in the immediate availability of unlimited amounts of the binding molecule. Based on these properties, peptide aptamers bear significant potential in various aspects of molecular medicine, which range from the functional analysis of given target proteins to the development of novel therapeutic agents.
I. PEPTIDE APTAMERS: THE METHODOLOGY AND PRACTICAL ASPECTS
Peptide aptamers are usually isolated from combinatorial expression libraries by screening *Address correspondence to this author at the Deutsches Krebsforschungszentrum, Programm Infektion und Krebs, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany; Tel.: 49 6221 424872 ; Fax: 49 6221 424852 ; E-mail: hoppe-seyler@dkfz.de systems based on the yeast two-hybrid technology, initially developed by Stanley Fields and coworkers [3] . Excellent reviews dealing with detailed technical aspects of the peptide aptamer technology are available [2, 4, 5] and therefore, the methodology will be described here only in a general form.
I.a. Basic Principle and the Role of the Scaffold
The peptide aptamer screening system basically consists of three components (Figure 1 ):
(i) a vector, which expresses the target protein (serving as the "bait") linked to a DNA-binding domain of a transcription factor (e. g. the DNAbinding domain of the yeast transcription factor GAL4; GAL4BD),
(ii) a vector, which expresses a library of different peptide aptamers (serving as the "prey"), linked to the transcriptional activation domain of a transcription factor (e. g. the GAL4 transcriptional activation domain, GAL4AD), and (iii) one or more reporter genes under the transcriptional control of recognition elements for the DNA-binding domain which is linked to the bait. These reporter genes are activated if the bait and the prey interact, thereby bringing the BD and AD in close proximity and forming a synthetic transcription factor (Figure 1 ). In yeast, these reporter genes are usually auxotrophic markers such as ADE2, HIS3, LYS2, LEU2, or URA3 which can be selected for by growing yeast transformants on media devoid of the appropriate nutrient. In addition, many yeast strains employed in two-hybrid screenings are constructed so as to contain enzymatic markers whose activities can be quantified, such as lacZ.
The peptide aptamer expression libraries are typically constructed by introducing double-stranded synthetic oligonucleotides of randomized sequences into a gene coding for a scaffold protein. For example, a randomized 60 bp (basepairs) oligonucleotide introduced into the unique RsrII site of the E. coli thioredoxin A (trxA) gene, will be expressed as a randomized 20-mer peptide on the surface of the TrxA protein, provided that there are no stop codons in the sequence [1] . Preferably, oligonucleotides are composed of triplets with the sequence NNK, where N is A, T, C, or G, and K is either G or T. These codons encode for all 20 amino acids, but result in only one stop codon. In most studies, the variable domains of the peptide aptamers have been chosen to have a length between 16-20 amino acids (aa). This length reflects a compromise, since the variable domain should be long enough to fold into many patterns of shape and charge on the one side, but, on the other side, should be short enough to circumvent too many stop codons and to allow structural determinations [1] .
Peptides that are anchored with both ends in a platform protein often exhibit a preferred conformation [6] . Theoretically, these so-called "constrained peptides (CPs)" possess a number of advantages compared to flexible peptides with free ends. Firstly, CPs usually have higher binding affinities than flexible peptides, most likely due to a decrease in conformational entropy of CPs in the unbound state. Indeed, the affinities of the variable peptide moieties to their target proteins decreased 10 to 1000-fold when they were removed from their supporting TrxA platform and tested in an unconstrained conformation [7, 8] . This indicates that the scaffold-mediated conformational constraint can significantly contribute to the binding affinity of peptide aptamers, albeit the degree can vary, depending on the sequence of the variable region. In addition, the possibility that amino-acid residues within the protein scaffold may contribute to target binding must be taken into account. Secondly, peptides displayed by a folded structure often exhibit a higher proteolytic stability relative to linear or unordered peptides [2] . This is an important consideration, if these molecules are used with the intent to inhibit target proteins intracellularly. Thirdly, the decrease in the conformational freedom of CPs should be helpful for the elucidation of their bioactive structure [6] , as a prerequisite to use these molecules as lead structures for drug design.
Figure (1).
The peptide aptamer screening system. In principle, the system consists of three components: (1) An expression vector for a target protein X, fused to a heterologous DNA binding domain (e. g. derived from the GAL4 transcription factor, GAL4BD). (2) An expression vector for randomized peptides (e. g. 20-mers), displayed in a constrained conformation from a scaffold protein (e. g. TrxA). The scaffold is linked to a heterologous transcriptional activation domain (e. g. GAL4AD), to a nuclear localization signal (NLS) and, optionally, to a tag sequence (e. g. HA-Tag). (3) A genetically modified yeast test strain containing one or multiple selectable markers (such as ADE2, HIS3, or URA3) under the transcriptional control of binding sites for the BD (e. g. Gal4BS). Only if a peptide binds to the target protein, a transcription factor is formed, in which the BD and AD are brought in close vicinity. This results in the transcriptional activation of the selectable marker gene.
Alternatively, it could be attempted to study the peptide aptamer/target protein complex in order to determine the bioactive structure of the aptamer.
The E. coli TrxA protein has been chosen as a scaffold for peptide aptamers due to its relatively small size (approx. 12 kD), its stability and solubility, and the fact that its three-dimensional structure is well known [1, 2] . Ideally, the platform protein itself should be functionally inert. In the case of TrxA, peptides are introduced into a constrained loop within the active center of the molecule, thereby destroying its enzymatic activity. Alternative scaffold proteins employed for the display of binding active peptide moieties include the green fluorescent protein (GFP) [9] [10] [11] and a catalytically inactive derivate of the staphylococcal nuclease (SNase) [11, 12] .
For yet little understood reasons, the variable domain of most TrxA-based peptide aptamers isolated thus far usually did not show significant homology to natural interaction partners for their target proteins. This may relate to the fact that they are conformationally constrained [5] . Indeed, the screening of an unconstrained peptide library for peptides binding to pRb led to the isolation of peptides that exhibited significant sequence homologies to natural pRb binding partners, similar to, for example, the screening of unconstrained peptides binding to the HPV E6 protein [13, 14] . Still, it is also possible to generate "rational peptide aptamers" by introducing naturally occuring interaction domains into the context of a TrxA scaffold. For example, the 18 aa interaction domain of the cellular E6AP protein was sufficient to mediate specific binding of a TrxA-based peptide aptamer to the HPV16 E6 protein, a natural interaction partner for E6AP [11] .
I. b. False Positives and Binding Specificity
As observed for the yeast two-hybrid technology in general, "false positive" signals, i. e. the activation of the marker gene in the absence of an interaction between the bait and the prey, can also occur during screening of peptide aptamer expression libraries. This can be caused by several mechanisms. For example, peptide aptamers that per se lead to the transcriptional activation of the promoter of a reporter gene (either directly or indirectly, e. g. via the modulation of yeast transcription factors) will score positive, although they do not interact with the bait. Similarly, peptide aptamers that stabilize the reporter gene product could elevate its activity above the phenotypic threshold. To avoid these types of false positives, the test strains employed in the peptide aptamer screening procedure usually posess multiple reporter genes under the control of different promoter sequences. In addition, we and others [15] observed that proteins with a low degree of intrinsic transactivation potential can be problematic baits for screening, since a significant number of peptide aptamers from the library will elevate the transcriptional activity of these baits above the threshold required for activation of the reporter gene, without biochemical evidence for a direct bait/prey interaction. This problem may be circumvented by deleting the transcriptional activation domain of the bait protein, before screening. In many cases, except for transcription factors with defined transactivation domains, this will require empiric truncations of the target protein since their transcriptional activation domains may be cryptic and not predictable from sequence analyses. This strategy is also required if one plans to screen with stronger transcriptional activators as baits, which per se already lead to an activation of the reporter gene above the phenotypic threshold.
It should also be noted that not every interaction that can be detected in the yeast two-hybrid system will necessarily take place in mammalian cells. For instance, a bait/prey interaction in the yeast two-hybrid system may be mediated by a bridging factor not present in mammalian cells. Also, since yeast cells are lacking certain posttranslational modification systems, the bait protein may be differentially modified (e. g. phosphorylated or glycosylated) in mammalian cells and no longer recognized by a peptide aptamer which scored positive for interaction in yeast.
In order to obtain additional evidence that the interaction between a given bait and peptide aptamer can take place in human cells, adaptations of the yeast two-hybrid system for mammalian cells can be utilized. Here, mammalian expression vectors for the bait and prey (linked to a DNA-binding domain, BD, and a transcriptional activation domain, AD, respectively) will lead to the transcriptional activation of a co-transfected reporter gene plasmid, e. g. containing the P. pyralis luciferase gene under the transcriptional control of recognition domains for the BD [e. g. 16].
In addition, co-precipitation studies can be performed in order to demonstrate an interaction between the bait and the prey in mammalian cell extracts, although a negative result does not always exclude an interaction in living cells, due to the sensitivity limits of the method. For in vitro binding analyses, it should also be taken into account that the target protein and/or the peptide aptamer may fold into different conformations, other than under in vivo conditions, and therefore not every intracellular interaction may be detectable using conventional in vitro binding assays.
It should also be noted that not every interaction between a peptide aptamer and its target protein will necessarily lead to the functional inhibition of the latter. As a matter of fact, in several studies, only a portion of the peptide aptamers that were isolated by virtue of their binding capacity, were able to act as potent inhibitors of their target protein. One explanation for this observation is the fact that individual peptide aptamers can bind to different domains on the target protein (see below) and, hence, binding may not interfere with the functionally critical interactions between the target protein and its natural binding partners. Insufficient expression levels of the aptamer may be another reason for the lack of functional inhibition, in particular if the target protein is abundantly expressed. Furthermore, one has to account for the possibility that the peptide aptamer is not directed into the relevant cellular compartment in which the target protein resides. In this case, it can be attempted to link the peptide aptamer to appropriate subcellular localization signals. Moreover, it is possible that the binding affinity of a peptide aptamer is sufficiently high to be detectable by interaction sensitive assays, such as the yeast two-hybrid system, but not high enough to functionally block the target protein under intracellular conditions. In this case, it can be attempted to increase the affinity of the peptide aptamer by "affinity maturation". This has been successfully demonstrated for Cdk2-binding peptide aptamers whose interaction domains have been mutagenized by error-prone PCR, followed by a selection for mutants with higher binding affinity, using calibrated yeast two-hybrid reporter genes [17] .
Another important issue concerns the specificity of the interaction. Here, the binding of the peptide aptamer to a spectrum of proteins, related or unrelated to the original bait, is examined. This can be performed by conventional two-hybrid analyses in yeast, in which the binding of specific aptamers to chosen baits is tested. In order to process a larger array of bait proteins, a method called "interaction mating" can be employed [2, 15] . According to this technique, haploid yeast of opposite mating types, expressing only the bait or the prey, respectively, are mated. This leads to the generation of diploids that express both the bait and the prey, and will activate a reporter gene, if they bind to each other. By generating interaction matrices, many preys and baits can be tested simultaneously for interaction, on a single plate [2, 15] .
II. FUNCTIONAL INHIBITION OF TARGET PROTEINS BY PEPTIDE APTAMERS
A major advantage of the peptide aptamer technology is the fact that the screening procedure takes place inside an eukaryotic organism. Therefore, the method itself already preselects for molecules that are stable and can bind to their target under intracellular conditions. This is an important aspect since many proteinaceous molecules, which have been selected by in vitro binding assays (e. g. phage display), do not bind to their targets inside the cell, for example due to a different folding pattern or instability of the molecule, under intracellular conditions [18] .
II. a. The inhibition of Cell Cycle Regulators In Vitro and In Vivo: Cdks and E2F
Pioneering work in the peptide aptamer field has been performed by Colas, Brent and coworkers, using the human Cdk2 protein as a target. Employing a Lex-A-based peptide aptamer screening system, they succeeded in isolating 14 peptide aptamers that bound to Cdk2 in vitro and exhibited binding affinities for their targets even in the nanomolar range (K d from 38-112 nM) [1] . Whereas all Cdk2-binding aptamers did not interact with a panel of control proteins, a subset of them were able to interact with other Cdks [1] . A likely explanation for this observation is provided by the fact that different peptide aptamers can bind to different domains on their target protein and some of them may therefore interact with regions which are conserved between closely related members of the same protein family. In fact, similar cross-binding to different, but related, members of the same protein family has also been shown for a subset of peptide aptamers binding to the cellular E2F-or HPV (human papillomavirus) E6 proteins [7, 19] . These aptamers could actually be particularly interesting molecules for target protein inhibition, since they may bind to domains which have been maintained during the evolution of individual protein families due to their biological importance.
The functional analysis of the Cdk2-binding aptamers revealed that they can efficiently interfere with the phosphorylation of the Cdk2 substrate histone H1 in vitro [1] . Among them, pep8 was chosen for further detailed analysis and found to bind at or near the active site of Cdk2 and to block the interaction between Cdk2 and histone H1 by competitive inhibition. Interestingly, however, pep8 interfered only with histone H1 phosphorylation but not with phosphorylation of the retinoblastoma tumor suppressor protein, pRb, which is another substrate for Cdk2 [8] . This distinct substrate specificity appears to be due to the existence of (at least partially) non-overlapping binding sites for histone H1 and pRb on Cdk2, with pep8 blocking sites on Cdk2 needed for the interaction with histone H1, but not with pRb [8] . Importantly, pep8 also showed a distinct effect in living cells since it inhibited progression through the G1 phase of the cell cycle, most likely through inhibition of phosphorylation of a subset of Cdk2 substrates [8] .
Moreover, Cdk-targeting peptide aptamers have also been shown to be functional in living animals. Peptide aptamers, which specifically bind to two Drosophila melanogaster Cdks, termed DmCdc2 and DmCd2c respectively, induced eye deformations (socalled rough eyes) typical for a cell cycle effect, a phenotype observed also in animals which are defective for the function of either DmCdc2 and DmCd2c [20] . This phenotypic effect was dosagedependent on the amounts of the respective peptide aptamers. In reverse, the eye deformations could specifically be suppressed by co-expressing the corresponding Drosophila Cdks, further demonstrating the specificity of action exerted by the Cdk-binding peptide aptamers. In line with a study demonstrating distinct mitotic defects following expression of Cyclin-Jbinding peptide aptamers in Drosophila embryos [21] , these results demonstrate that peptide aptamers also maintain their binding specificity in living organisms, where they can work as specific inhibitors of their target proteins.
Another cell cycle regulatory factor that has been successfully targeted for functional inactivation by peptide aptamers is the transcription factor E2F1. This factor belongs to a protein family that plays a crucial role for cell cycle regulation, DNA replication and the DNA damage response pathway [22] . The deregulation of E2F activities has been linked to cancer development. Fabrizzio and coworkers isolated a series of peptide aptamers that bound to E2F1 [7] . Interestingly, in contrast to many other TrxA-constrained peptide aptamers isolated for other target proteins, one of the E2F1-binding aptamers exhibited a pronounced sequence homology to the heterodimerization domain of DP1, a natural E2F1-interaction partner. As observed for the Cdk2-targeting peptide aptamers, the E2F-binding peptide aptamers interfered with specific biochemical activities of their target protein, such as the binding of E2F to DNA in vitro. Moreover, introduction of an E2F-binding peptide aptamer into living cells resulted in growth inhibition by arresting the cells in the G1 phase of the cell cycle [7] . These peptide aptamers may therefore serve as new model molecules for the generation of therapeutic agents with anti-proliferative activities.
II. b. The Interruption of Signal Transduction by Peptide Aptamers: RAS, Trio, EGFR
Activating mutations of the growth-promoting RAS genes are found in approximately 20% of all human cancers and can reach extremely high frequencies for particular tumor types, being detectable, for example, in approximately 90% of pancreatic and 50% of colorectal cancers. Therapeutic agents that can interfere with aberrant Ras signalling are therefore considered to bear great potential for the development of novel cancer treatments [23] . In order to reduce possible side-effects, such molecules should preferentially be able to specifically target mutant Ras in the tumor cells without interfering with the function of wildtype Ras in normal cells.
The "two-bait interaction trap" (Figure 2 ) has been developed as a variation of the peptide aptamer screening system, in order to generate discriminatory peptide aptamers which can differentiate between wildtype and oncogenic alleles of Ras [24, 25] . In a first step, peptide aptamers binding to mutant (mt) Ras protein were isolated by the conventional peptide aptamer screening procedure, as schematically illustrated in Figure 1 . In a second step, the two bait two-hybrid system was employed. For this, wildtype (wt) and mt Ras proteins were simultaneously expressed in yeast, fused to two different DNA binding domains, namely to the LexA and TetR binding domain, respectively [24] . In the yeast test strain used, the mtRas/TetR fusion protein mediates the activation of a TetOp-URA3 reporter, if it is bound by a peptide aptamer linked to a transcriptional activation domain (AD) (Figure 2) . On the other side, a peptide aptamer that binds to the wtRas/LexA fusion protein will activate Figure (2) . The two bait two-hybrid system. Two different baits, X and Y (e. g. mtRas and wtRas) are fused to two different DNA binding domains (e. g. TetR and LexA, respectively) and expressed in the same yeast cell. A peptide aptamer, linked to a transcriptional activation domain, that selectively binds to bait X (e. g. mtRas/TetR) will stimulate only the TetOp-URA3 marker gene, but not the LexOp-lacZ reporter. This results in growth of the yeast on uracil-deficient medium (activation of URA3), however, the colonies will be white on X-Gal plates (no activation of lacZ). In contrast, non-discriminatory aptamers that bind to both X and Y will activate both markers. They will also grow on uracil-deficient medium, but will appear blue on X-Gal plates.
a LexAOp-lacZ reporter. Consequently, the application of two-bait two-hybrid system resulted in two readouts: (i) peptide aptamers, which bound to both mtRas and wtRas, induced growth of colonies on uracil-deficient medium which were blue on X-Gal (activation of both lacZ and URA3) whereas (ii) peptide aptamers that only bound to mtRas also grew on uracil-deficient medium, but formed white colonies on X-Gal (activation of URA3, but no activation of lacZ) [25] . The discriminatory aptamers isolated by this method were able to block the interaction between oncogenic Ras and c-Raf1 in vitro and inhibited Ras-mediated activation of c-Raf1 within living cells [25] . Thus, peptide aptamers can be generated, which specifically target the products of different alleles of the same gene (e. g. mutant versus non-mutant). These molecules may serve as a basis to develop allele-specific therapeutic agents which, for example for mtRas-expressing cancers, may preferentially affect tumor cells.
Another signal transduction factor that has been sucessfully inhibited by peptide aptamers is the Trio protein, a Rho-guanine exchange factor (Rho-GEF) [26] . Trio is involved in the control of neuronal cell migration and axon guidance. A Trio-binding peptide aptamer blocked the exchange activity of the Trio-GEFD2 domain towards the RhoA protein. It contained a 42 aa peptide moiety which, even when it was removed from its supporting TrxA scaffold and linked in an unconstrained conformation 3' to GFP, blocked the neurite retraction phenotype of the neuronal cell line PC12 [26] .
In addition, TrxA-based peptide aptamers have been recently generated against the intracellular domain of the epidermal growth factor receptor, EGFR [27] . This receptor is considered to be an attractive therapeutic target since its activity is found to be dysregulated in a variety of cancers, such as carcinoma of the breast [28] . One of the peptide aptamers isolated in this study inhibited the phosphorylation of specific tyrosine residues of EGFR. This was associated with an impairment of EGF-induced phosphorylation of the Stat3 transcription factor and interfered with Stat3-mediated transcriptional activation. At the cellular level, these events were linked to a reduced proliferation rate and impaired colony formation capacity of EGFRexpressing cells. Further studies indicated that the EGFR-binding peptide moiety of the aptamer, flanked by cysteine residues on either side, did not necessarily require the TrxA scaffold for functional inhibition of EGFR signaling [27] .
II. c. Inhibition of Viral Proteins by Peptide Aptamers: HPV and HBV
As non-cellular factors, viral proteins are attractive therapeutic targets for the generation of inhibitory peptide aptamers, since the latter should exert their effects specifically in diseased cells. For example, peptide aptamers targeting human papillomavirus (HPV) oncoproteins should selectively affect HPV-positive tumor cells but not normal cells, which are devoid of the virus. HPV-positive tumors, such as cervical cancers, regularly express two viral oncoproteins, E6 and E7. The E6 protein is considered to exert its antiapoptotic activity, at least in part, by inducing the proteolytic degradation of p53 [29] . Consequently, peptide aptamers that targeted the HPV16 E6 protein increased p53 levels and induced apoptosis selectively in HPV-positive cancer cells, without affecting HPVnegative cells [19] . These peptide aptamers may therefore serve as novel model molecules to generate therapeutic agents to treat HPV-associated dysplasias and tumors. In this context, it is noteworthy that apoptosis-inducing molecules could be of particular therapeutic benefit since they may not require continuous application. Similar strategies aiming at the correction of the apoptosis deficiency of tumor cells can also be envisioned by targeting cellular anti-apoptotic proteins which are overexpressed, or even exclusively expressed in tumor cells, such as certain members of the IAP (inhibitors of apoptosis) [30] or bcl-2 families [31] .
Notably, among the 17 peptide aptamers that targeted HPV16 E6, there were two which also bound to the E6 protein of HPV18, representing another oncogenic HPV type, whereas they did not interact with the E6 proteins of HPV types that are usually not associated with cancer (e. g. HPV6 and HPV11) [19] . Thus, as described for the Cdk-2-and E2F-binding peptide aptamers, they may bind to protein domains that are conserved between different members of the same protein family and which, in this case, are present only in E6 proteins with transforming potential.
Peptide aptamers have also been generated against the second transforming HPV oncogene, E7, and were reported to induce apoptosis in HPV-positive cancer cells [32] . This contrasts with the assumption by most researchers that E7 primarily rather exhibits proapoptotic activity and inhibition of E7 should therefore block apoptosis. Yet, it may be possible that E7 exerts some anti-apoptotic effects under certain experimental conditions, which is an open issue that should be further investigated.
The inhibitory potential of peptide aptamers also extends to structural virus proteins. For hepatitis B virus (HBV), a series of aptamers have been generated that target the viral core protein, which multimerizes in order to form the viral capsid [33] . Since HBV genome replication and maturation takes place within newlyformed viral capsids in the cytoplasm of the infected host cell, it was reasoned that peptide aptamers that block capsid assembly should also block progression of the viral life cycle. Indeed, among a series of peptide aptamers that specifically interacted with the HBV core protein in vitro and within mammalian cells, one efficiently blocked capsid formation and, consequently, inhibited viral replication and virion production [16] . This approach of generating peptide aptamers against viral structural proteins should be broadly applicable, in order to interfere with the life cycle of many different virus types.
II. d. Smart Peptide Aptamers: Modifiers and Transporters
Many peptide aptamers are believed to inhibit their target protein by binding to functionally critical surface domains, thereby competitively interfering with the binding of natural interaction partners. Yet, peptide aptamer derivatives have been developed that extend the range of functional manipulations. For example, peptide aptamers fused to a nuclear localization sequence (NLS) resulted in the translocation of their target proteins into the cell nucleus [17] . This is reminiscent of studies examining artificial PDZ protein recognition modules, which, when fused to a NLS, also directed their target proteins into the cell nucleus [34] . Thus, it may be possible to develop chimeric peptide aptamers, fused to specific intracellular localization signals, into "transporters" that functionally inhibit their protein targets by translocating them into cellular compartments in which they are not active. In reverse, it may also be possible to use such transporters to relocate mislocalized proteins into the right cellular compartment, for functional reactivation.
In addition, chimeric peptide aptamers have been generated, which were able to covalently modify their target protein in living cells. Fusion of the catalytic domain of a ubiquitin ligase to a Cdk2-binding peptide aptamer led to the specific ubiquitination of Cdk2 in vivo [17] . These experiments indicate that peptide aptamers could also be utilized to specifically modulate their target proteins, e. g. tagging them for proteolytic degradation by the ubiquitin system.
III. PEPTIDE APTAMERS AS "PERTUBAGENS": MOLECULAR TOOLS FOR FORWARD GENETICS
As discussed up to here, peptide aptamers have been developed and successfully employed for "reverse genetics", i. e. in order to interfere with the function of a given gene product and then determine the resulting phenotype. In this sense, peptide aptamers extend the spectrum of other genetic tools, such as dominant-negative proteins, intracellular antibodies, antisense and siRNAs, or nucleic acid aptamers.
However, peptide aptamers have also been shown to be valuable tools for "forward genetics" which classically involves the isolation of cells with an altered phenotype and the subsequent identification of the responsible lesion. This is usually difficult to achieve by mutational analysis in diploid organisms, since only dominant mutations can be readily detected. However, peptide aptamers can act as so-called "pertubagens" [4, 5, 10] , i. e. as dominant agents that "mutate" gene function at the protein level, without altering the genetic material. This scenario typically involves three steps: At first, a randomized peptide aptamer expression library is expressed intracellularly, resulting in the expression of a large number of pertubagens that can disrupt specific biochemical interactions. In a second step, cellular variants exhibiting the desired phenotype will be selected. Thirdly, the pertubagen can be identified, retrieved and sequenced, and its cellular targets determined and characterized. As discussed below, this methodology led to the identification of biological pathways responsible for distinct cellular phenotypes and allowed the identification of crucial biochemical components involved in their regulation.
For example, peptide aptamers have been employed as pertubagens that inhibit the yeast pheromone pathway, transcriptional silencing, or the spindle cell checkpoint [10, 12, 35] . Following the isolation of peptide aptamers from cells exhibiting the desired phenotype, the binding targets for these pertubagens were identified by conventional yeast twohybrid analyses, thereby delineating key components involved in the individual pathway regulations. Notably, information about the molecular targets of a given pertubagen may also be obtained by transcript arrays or mass spectrometry investigation of proteins that interact with the pertubagen [12] . Overall, this experimental approach should enable the identification of peptide aptamers that interfere with specific biochemical cascades and identify targets for functional inhibition. This can also be of therapeutic significance for humans, because many biological pathways are conserved between yeast and mammals.
In addition, by employing an adaptation of this technology to bacterial systems, peptide aptamers were identified from a randomized expression library, which specifically interfered with the activity of thymidilate synthase, a virulence factor for human pathogens, such as Shigella flexneri or Legionella pneumophila [36] . Furthermore, a number of peptide aptamers acting more broadly as bacteriostatic and bacteriocidic agents were identified. Thus, peptide aptamers may also be valuable tools to identify novel molecular targets for antibacterial drug development.
This approach of "dominant effector genetics" has been extended to human cells. Intracellular expression of randomized peptides from a retroviral construct led to the identification of peptides that mediated resistance to the anti-cancer drug Taxol [37] . In this system, the peptides were expressed within the context of a small synthetic scaffold that was based on the dimerizing potential of the sequence EFLIVKS, which, when linked to both sides of a peptide, is believed to create a non-covalent artificial loop scaffold [38, 39] . Subsequent studies showed that the increased resistance to Taxol was linked to an upregulation of the ABCB1 gene, which encodes a trans-membrane protein that has been previously implied in the regulation of Taxol resistance. Since the peptide aptamer that increased Taxol resistance bound to proteasome subunits, as revealed by yeast two-hybrid screens, the increased ABCB1 expression may be related to a thus far not further elucidated inhibition of proteasome-mediated protein degradation [37] .
IV. PERSPECTIVES
Peptide aptamers represent a new class of molecules with broad potential for both basic and applied aspects of molecular medicine. As molecular tools, they have been successfully employed for functional studies of given target proteins, both in vitro and in vivo. In this context, peptide aptamers represent an interesting alternative to more traditional approaches in reverse genetics, such as knockout mutations, to assess the function of a given gene product, at the intracellular level. On the other hand, by using them as pertubagens, peptide aptamers can also be useful tools for the identification and delineation of both known and unknown components of distinct biochemical pathways which are linked to a certain cellular phenotype.
In a more applied aspect, it could be envisioned that peptide aptamers can be developed into diagnostic tools. Based on their binding specificity and affinity, it may be possible to employ them for the detection of a target protein, similar to monoclonal antibodies. In addition, the peptide aptamer technology should extend the range of availabe high-throughput protein arrays [40] for expression profiling of genomes. In this context, the ability of peptide aptamers to differentiate between closely related members of the same protein family and to even recognize single point mutants of the same protein should be extremely helpful; as a matter of fact, it seems plausible that peptide aptamers can be generated, which are capable to differentiate between different post-translationally modified forms of the same protein.
Moreover, peptide aptamers have important implications for different therapeutic prospects. Clearly, they can be employed to validate known factors as potential therapeutic targets, by assessing the biological consequences of their intracellular inhibition. Due to their ability to bind to different domains on their target protein (Figure 3) , peptide aptamers are able to selectively block distinct activities [8] , whereas antisense or siRNA approaches abolish all protein interactions in which the target gene product is involved. Moreover, their use as pertubagens (see above) should also allow the identification of yet unknown proteins that may constitute new therapeutic targets for functional inhibition.
In addition, both indirect and direct therapeutic potential resides in the aptamer molecules themselves. The physical properties of the peptide aptamers, such as the small size of the variable protein moiety and its conformationally constrained display from structurally well-characterized scaffold proteins, should be helpful for the elucidation of their bioactive structure. On this basis, peptide aptamers may prove useful for drug design, e. g. as novel lead structures for the synthesis of non-peptide mimetics. Furthermore, the ability of peptide aptamers to bind to specific regions of the target protein may provide three-dimensional information about crucial docking sites for small molecule inhibitors on the target protein. From this data, it can be attempted to fit in selections of designed inhibitory small molecules into the docking site [41] .
Moreover, the peptide aptamers themselves may be developed into therapeutic agents. In principle, the coding sequences of an inhibitory peptide could be 
